This is a StreetInsider.com Premium Only Page

(QLGN) –

Apr 16, 2024 04:10 PM Form 8-K Qualigen Therapeutics, For: Apr 11

Apr 10, 2024 08:04 AM Qualigen Therapeutics' (QLGN) Novel Direct Pan-RAS Inhibitors Presented at AACR

Apr 10, 2024 08:00 AM Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

Apr 8, 2024 06:02 AM Form 10-K Qualigen Therapeutics, For: Dec 31

Apr 1, 2024 02:36 PM Form NT 10-K Qualigen Therapeutics, For: Dec 31

Mar 28, 2024 04:06 PM Form 8-K Qualigen Therapeutics, For: Mar 25

Feb 27, 2024 07:00 AM Form 8-K Qualigen Therapeutics, For: Feb 25

Feb 22, 2024 04:11 PM Form 8-K Qualigen Therapeutics, For: Feb 15

Dec 7, 2023 04:16 PM Form 8-K Qualigen Therapeutics, For: Dec 05

Nov 22, 2023 04:31 PM Form 8-K Qualigen Therapeutics, For: Nov 20

Nov 14, 2023 08:44 PM Form 8-K Qualigen Therapeutics, For: Nov 14

Nov 14, 2023 08:42 PM Form 10-Q Qualigen Therapeutics, For: Sep 30

Nov 8, 2023 02:16 PM Form 8-K Qualigen Therapeutics, For: Nov 07

Nov 7, 2023 08:30 AM Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Oct 23, 2023 08:30 AM Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Oct 23, 2023 08:30 AM Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Oct 17, 2023 08:31 AM Form 8-K Qualigen Therapeutics, For: Oct 17

Oct 3, 2023 06:03 AM Form S-1/A Qualigen Therapeutics,

Sep 29, 2023 04:49 PM Form 424B3 Qualigen Therapeutics,

Sep 28, 2023 04:17 PM Form 8-K Qualigen Therapeutics, For: Sep 22

Sep 27, 2023 08:30 AM Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023

Sep 8, 2023 06:03 AM Form EFFECT Qualigen Therapeutics,

Sep 1, 2023 04:15 PM Form POS AM Qualigen Therapeutics,

Aug 17, 2023 08:31 AM Qualigen Therapeutics (QLGN) Partners with TD2 for Phase 1 Clinical Development of QN-302

Aug 17, 2023 08:30 AM Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors

Aug 15, 2023 10:04 AM Form 8-K Qualigen Therapeutics, For: Aug 15

Aug 15, 2023 08:30 AM Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023

Aug 14, 2023 04:17 PM Form 10-Q Qualigen Therapeutics, For: Jun 30

Aug 4, 2023 04:31 PM Form 8-K Qualigen Therapeutics, For: Aug 01

Aug 1, 2023 08:35 AM Form 8-K Qualigen Therapeutics, For: Aug 01

Aug 1, 2023 08:30 AM Qualigen Therapeutics (QLGN) Granted FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302

Aug 1, 2023 08:30 AM Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Jul 26, 2023 05:25 PM Form 8-K Qualigen Therapeutics, For: Jul 20

Jul 24, 2023 08:15 AM Qualigen Therapeutics (QLGN) Divests FastPack Diagnostics Business

Jul 24, 2023 08:15 AM Qualigen Therapeutics Divests FastPack® Diagnostics Business

Jul 13, 2023 05:30 PM Form 8-K Qualigen Therapeutics, For: Jul 13

Jul 7, 2023 05:09 PM Form 10-K/A Qualigen Therapeutics, For: Dec 31

Jun 26, 2023 05:25 PM Form 8-K Qualigen Therapeutics, For: Jun 20

Jun 13, 2023 05:16 PM Form S-1 Qualigen Therapeutics,

Jun 5, 2023 08:15 AM Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Jun 2, 2023 04:11 PM Form ARS Qualigen Therapeutics, For: Dec 31

Jun 2, 2023 04:06 PM Form DEF 14A Qualigen Therapeutics, For: Jun 02

May 19, 2023 08:20 AM Form 8-K Qualigen Therapeutics, For: May 16

May 16, 2023 08:00 AM Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023

May 15, 2023 05:14 PM Form PRE 14A Qualigen Therapeutics, For: May 15

May 15, 2023 04:09 PM Form 10-Q Qualigen Therapeutics, For: Mar 31

May 5, 2023 04:16 PM Form 8-K Qualigen Therapeutics, For: May 04

May 2, 2023 04:30 PM Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

May 2, 2023 04:27 PM Form 10-K Qualigen Therapeutics, For: Dec 31

May 2, 2023 08:15 AM Qualigen Therapeutics’ Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting